Business Description
Aspen Pharmacare Holdings Ltd
ISIN : ZAE000066692
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.42 | |||||
Debt-to-EBITDA | 4.48 | |||||
Interest Coverage | 4.5 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.52 | |||||
Beneish M-Score | -2.33 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.5 | |||||
3-Year EBITDA Growth Rate | 10.1 | |||||
3-Year EPS without NRI Growth Rate | 7.8 | |||||
3-Year FCF Growth Rate | -24.4 | |||||
3-Year Book Growth Rate | 8.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 10.19 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
12-1 Month Momentum % | -7.02 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.92 | |||||
Quick Ratio | 1.09 | |||||
Cash Ratio | 0.51 | |||||
Days Inventory | 285.73 | |||||
Days Sales Outstanding | 101.76 | |||||
Days Payable | 128.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.23 | |||||
3-Year Average Share Buyback Ratio | 0.8 | |||||
Shareholder Yield % | -6.74 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 43.92 | |||||
Operating Margin % | 20.02 | |||||
Net Margin % | 11.4 | |||||
FCF Margin % | 3.15 | |||||
ROE % | 5.91 | |||||
ROA % | 3.71 | |||||
ROIC % | 6.07 | |||||
ROC (Joel Greenblatt) % | 21.3 | |||||
ROCE % | 7.3 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 20.14 | |||||
PE Ratio without NRI | 14.64 | |||||
Shiller PE Ratio | 15 | |||||
Price-to-Owner-Earnings | 86.11 | |||||
PEG Ratio | 2.76 | |||||
PS Ratio | 2.3 | |||||
PB Ratio | 1.15 | |||||
Price-to-Tangible-Book | 8.22 | |||||
Price-to-Free-Cash-Flow | 72.46 | |||||
Price-to-Operating-Cash-Flow | 15.64 | |||||
EV-to-EBIT | 15.2 | |||||
EV-to-EBITDA | 15.2 | |||||
EV-to-Revenue | 2.87 | |||||
EV-to-FCF | 90.59 | |||||
Price-to-Projected-FCF | 1.03 | |||||
Price-to-Median-PS-Value | 0.85 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.78 | |||||
Price-to-Graham-Number | 2.31 | |||||
Earnings Yield (Greenblatt) % | 6.58 | |||||
FCF Yield % | 1.38 | |||||
Forward Rate of Return (Yacktman) % | 7.83 |